EA201100580A1 - Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы - Google Patents

Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы

Info

Publication number
EA201100580A1
EA201100580A1 EA201100580A EA201100580A EA201100580A1 EA 201100580 A1 EA201100580 A1 EA 201100580A1 EA 201100580 A EA201100580 A EA 201100580A EA 201100580 A EA201100580 A EA 201100580A EA 201100580 A1 EA201100580 A1 EA 201100580A1
Authority
EA
Eurasian Patent Office
Prior art keywords
imidazopiridazincarbonitrile
kinase inhibitors
formula
imidazopyridazines
inhibit
Prior art date
Application number
EA201100580A
Other languages
English (en)
Other versions
EA018163B1 (ru
Inventor
Брайан Финк
Либин Чэнь
Ашвиникумар Гавай
Лици Хэ
Сунг-Хун Ким
Эндрю Нэйшн
Юфэнь Чжао
Литай Чжэн
Original Assignee
Бристол-Маерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Маерс Сквибб Компани filed Critical Бристол-Маерс Сквибб Компани
Publication of EA201100580A1 publication Critical patent/EA201100580A1/ru
Publication of EA018163B1 publication Critical patent/EA018163B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Abstract

В изобретении представлены соединения формулы (I)и их фармацевтически приемлемые соли. Имидазопиридазины формулы (I) подавляют активность протеинкиназы, что позволяет использовать их в качестве противоопухолевых агентов.
EA201100580A 2008-10-09 2009-10-08 Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы EA018163B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10404508P 2008-10-09 2008-10-09
PCT/US2009/059968 WO2010042699A1 (en) 2008-10-09 2009-10-08 Imidazopyridazinecarbonitriles useful as kinase inhibitors

Publications (2)

Publication Number Publication Date
EA201100580A1 true EA201100580A1 (ru) 2011-10-31
EA018163B1 EA018163B1 (ru) 2013-05-30

Family

ID=41718919

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201100580A EA018163B1 (ru) 2008-10-09 2009-10-08 Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы

Country Status (28)

Country Link
US (3) US8252795B2 (ru)
EP (1) EP2350081B1 (ru)
JP (1) JP5560278B2 (ru)
KR (1) KR20110075010A (ru)
CN (1) CN102245609B (ru)
AR (1) AR073818A1 (ru)
AU (1) AU2009302360B2 (ru)
BR (1) BRPI0920135A2 (ru)
CA (1) CA2739782A1 (ru)
CL (1) CL2011000777A1 (ru)
CO (1) CO6361936A2 (ru)
CY (1) CY1114539T1 (ru)
DK (1) DK2350081T3 (ru)
EA (1) EA018163B1 (ru)
ES (1) ES2426951T3 (ru)
HK (1) HK1154002A1 (ru)
HR (1) HRP20130787T1 (ru)
IL (1) IL211693A (ru)
MX (1) MX2011003304A (ru)
NZ (1) NZ591712A (ru)
PE (1) PE20110411A1 (ru)
PL (1) PL2350081T3 (ru)
PT (1) PT2350081E (ru)
SI (1) SI2350081T1 (ru)
SM (1) SMT201300109B (ru)
TW (1) TWI491610B (ru)
WO (1) WO2010042699A1 (ru)
ZA (1) ZA201102423B (ru)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2240488B1 (en) * 2008-02-06 2016-11-02 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
US9587033B2 (en) 2010-11-15 2017-03-07 University Of Florida Research Foundation, Inc. Therapeutic and diagnostic applications targeting TNK-1
CN103370322B (zh) 2010-12-17 2016-02-10 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的2-取代的咪唑并吡嗪
JP5824065B2 (ja) 2010-12-17 2015-11-25 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ 過剰増殖性障害の治療におけるｍｐｓ−１およびｔｋｋ阻害剤として使用するための６置換イミダゾピラジン
CN103415518A (zh) 2010-12-17 2013-11-27 拜耳知识产权有限责任公司 在过度增殖性病症的治疗中用作mps-1和tkk抑制剂的咪唑并吡嗪
WO2012148792A1 (en) * 2011-04-26 2012-11-01 Merck Sharp & Dohme Corp. Heterocyclic compounds as b-raf inhibitors for treatment of cancer
EP2825540B1 (en) 2012-03-14 2016-09-14 Bayer Intellectual Property GmbH Substituted imidazopyridazines
AU2013234955A1 (en) 2012-03-23 2014-11-13 Dennis Brown Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo
TW201414737A (zh) 2012-07-13 2014-04-16 必治妥美雅史谷比公司 作爲激酶抑制劑之咪唑并三□甲腈
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
TW201437211A (zh) * 2013-03-01 2014-10-01 Bayer Pharma AG 經取代咪唑并嗒□
US9586958B2 (en) 2013-06-11 2017-03-07 Bayer Pharma Aktiengesellschaft Prodrug derivatives of substituted triazolopyridines
CN105764501A (zh) 2013-07-26 2016-07-13 现代化制药公司 改善比生群治疗效益的组合物
AR097543A1 (es) * 2013-09-06 2016-03-23 Lexicon Pharmaceuticals Inc COMPUESTOS BASADOS EN IMIDAZO[1,2-b]PIRIDAZINA, COMPOSICIONES QUE LOS COMPRENDEN Y SUS MÉTODOS DE USO
TW201542550A (zh) * 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
GB201403536D0 (en) * 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
ES2828733T3 (es) 2015-11-18 2021-05-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
CA3028727A1 (en) 2016-06-24 2017-12-28 Polaris Pharmaceuticals, Inc. Ck2 inhibitors, compositions and methods thereof
BR112019002576A2 (pt) * 2016-08-10 2019-05-21 Takeda Pharmaceutical Company Limited composto, medicamento¸ métodos para inibição de gcn2 em um mamífero e para a profilaxia ou tratamento de câncer em um mamífero, e, uso do composto ou um sal do mesmo
KR102611856B1 (ko) 2016-11-17 2023-12-07 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn-알파의 이미다조피리다진 조정제
CR20190424A (es) 2017-03-30 2019-11-04 Hoffmann La Roche Isoquinolinas como inhibidores de hpk1
US11339157B1 (en) 2017-10-24 2022-05-24 Bayer Aktiengesellschaft 4H-pyrrolo[3,2-c]pyridin-4-one derivatives
CN109988150B (zh) 2017-12-29 2022-04-12 江苏中旗科技股份有限公司 N-烷基-n-氰基烷基苯甲酰胺类化合物及其应用
BR112020013313B1 (pt) 2017-12-29 2023-10-31 Jiangsu Flag Chemical Industry Co., Ltd Composto de pirazolamida de fórmula geral i, composto de fórmula ii, método para preparar um composto de fórmula geral i, uso do composto de fórmula geral i, composição inseticida e método para controlar pragas
WO2019128871A1 (zh) 2017-12-29 2019-07-04 江苏中旗科技股份有限公司 N-烷基-n-氰基烷基苯甲酰胺类化合物及其应用
BR112020015396A2 (pt) * 2018-01-29 2020-12-08 Merck Patent Gmbh Inididores de gcn2 e usos dos mesmos
US11612606B2 (en) 2018-10-03 2023-03-28 Genentech, Inc. 8-aminoisoquinoline compounds and uses thereof
WO2020191091A1 (en) 2019-03-19 2020-09-24 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic aza-benzothiophene and aza-benzofuran compounds
CA3137611A1 (en) 2019-04-24 2020-10-29 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
EP3959212A1 (en) 2019-04-24 2022-03-02 Bayer Aktiengesellschaft 4h-pyrrolo[3,2-c]pyridin-4-one compounds
KR20220004103A (ko) 2019-04-24 2022-01-11 바이엘 악티엔게젤샤프트 4H-피롤로[3,2-c]피리딘-4-온 화합물
CA3177214A1 (en) 2020-03-31 2021-10-07 Bayer Aktiengesellschaft 3-(anilino)-2-[3-(3-alkoxy-pyridin-4-yl]-1,5,6,7-tetrahydro-4h-pyrrolo[3,2-c]pyridin-4-one derivatives as egfr inhibitors for the treatment of cancer
MX2022015038A (es) 2020-05-29 2023-01-04 Boehringer Ingelheim Animal Health Usa Inc Compuestos heterociclicos como anthelminticos.
WO2023147372A1 (en) * 2022-01-25 2023-08-03 Kinnate Biopharma Inc. Inhibitors of cdk4/6 kinase
WO2024039767A1 (en) * 2022-08-18 2024-02-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Imidazo[1,2-b]pyridazine inhibitors of cyclin-dependent kinases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE340176T1 (de) 1996-08-28 2006-10-15 Pfizer Substituierte 6,5-heterobicyclische-derivate
ATE300540T1 (de) 2000-04-27 2005-08-15 Yamanouchi Pharma Co Ltd Imidazopyridin-derivate
AU2003255845A1 (en) 2002-08-22 2004-03-11 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
BR0316363A (pt) 2002-11-15 2005-10-04 Idenix Cayman Ltd Nucleosìdeos 2'-ramificado e mutação de flaviviridae
JP4758909B2 (ja) * 2003-12-31 2011-08-31 シェーリング−プラウ・リミテッド イミダゾ［１，２−ｂ］ピリダジン誘導体を使用することによる動物における寄生生物の制御
WO2005080355A1 (en) 2004-02-12 2005-09-01 Neurogen Corporation Imidazo-pyridazines, triazolo-pyridazines and related benzodiazepine receptor ligands
CN101048158A (zh) * 2004-08-13 2007-10-03 健泰科生物技术公司 利用atp的酶的噻唑－类抑制剂
US20080167314A1 (en) * 2004-12-28 2008-07-10 Osamu Uchikawa Condensed Imidazole Compound And Use Thereof
WO2007025043A2 (en) 2005-08-23 2007-03-01 Idenix Pharmaceuticals, Inc. Seven-membered ring nucleosides
US20070049591A1 (en) 2005-08-25 2007-03-01 Kalypsys, Inc. Inhibitors of MAPK/Erk Kinase
WO2007035428A1 (en) 2005-09-15 2007-03-29 Bristol-Myers Squibb Company Met kinase inhibitors
US7723336B2 (en) * 2005-09-22 2010-05-25 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US20070078136A1 (en) * 2005-09-22 2007-04-05 Bristol-Myers Squibb Company Fused heterocyclic compounds useful as kinase modulators
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
BRPI0714665A2 (pt) * 2006-08-04 2012-03-13 Takeda Pharmaceutical Company Limited Composto, pró-droga, agente farmacêutico, e, método para a profilaxia ou tratamento do câncer
EP1900739A1 (en) 2006-08-30 2008-03-19 Cellzome Ag Diazolodiazine derivatives as kinase inhibitors
WO2008030579A2 (en) 2006-09-07 2008-03-13 Biogen Idec Ma Inc. Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
WO2008029152A2 (en) 2006-09-08 2008-03-13 Summit Corporation Plc Treatment of duchenne muscular dystrophy
EP1911451A1 (en) * 2006-10-10 2008-04-16 INSERM (Institut National de la Santé et de la Recherche Medicale) Protein-kinase CK2 inhibitors and their therapeutic applications
CA2667960A1 (en) * 2006-10-30 2008-05-08 Novartis Ag Imidazopyridazines as pi3k lipid kinase inhibitors
EP2155753A1 (en) * 2007-05-09 2010-02-24 Novartis Ag Substituted imidazopyridazines as pi3k lipid kinase inhibitors
EP2240488B1 (en) * 2008-02-06 2016-11-02 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
TWI491610B (zh) * 2008-10-09 2015-07-11 必治妥美雅史谷比公司 作為激酶抑制劑之咪唑并嗒腈

Also Published As

Publication number Publication date
US20100113458A1 (en) 2010-05-06
IL211693A (en) 2015-06-30
CY1114539T1 (el) 2016-10-05
US20140179674A1 (en) 2014-06-26
JP2012505235A (ja) 2012-03-01
JP5560278B2 (ja) 2014-07-23
PL2350081T3 (pl) 2013-10-31
CN102245609A (zh) 2011-11-16
EP2350081A1 (en) 2011-08-03
AU2009302360A1 (en) 2010-04-15
SMT201300109B (it) 2013-11-08
ZA201102423B (en) 2012-09-26
AU2009302360B2 (en) 2014-12-11
US20120283241A1 (en) 2012-11-08
NZ591712A (en) 2012-10-26
BRPI0920135A2 (pt) 2019-09-24
TW201018686A (en) 2010-05-16
US9371328B2 (en) 2016-06-21
WO2010042699A1 (en) 2010-04-15
CN102245609B (zh) 2016-03-09
ES2426951T3 (es) 2013-10-25
CA2739782A1 (en) 2010-04-15
HK1154002A1 (en) 2012-04-13
EP2350081B1 (en) 2013-07-03
HRP20130787T1 (en) 2013-09-30
TWI491610B (zh) 2015-07-11
IL211693A0 (en) 2011-06-30
PT2350081E (pt) 2013-09-24
KR20110075010A (ko) 2011-07-05
US8252795B2 (en) 2012-08-28
EA018163B1 (ru) 2013-05-30
PE20110411A1 (es) 2011-06-22
DK2350081T3 (da) 2013-10-14
CL2011000777A1 (es) 2011-08-12
CO6361936A2 (es) 2012-01-20
AR073818A1 (es) 2010-12-01
SI2350081T1 (sl) 2013-11-29
MX2011003304A (es) 2011-04-21

Similar Documents

Publication Publication Date Title
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
EA201190227A1 (ru) Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ
EA201490971A1 (ru) Производные урацила в качестве ингибиторов axl и c-met киназы
TN2011000293A1 (en) Protein kinase inhibitors
EA202090291A2 (ru) Производные бипиразола в качестве ингибиторов jak
EA201071339A1 (ru) Фосфорсодержащие производные в качестве ингибиторов киназы
EA200901488A1 (ru) Замещенные имидазолопиридазины, как ингибиторы липидкиназы
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
EA201190158A1 (ru) Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
EA200900983A1 (ru) Соединения и композиции в качестве ингибиторов киназы
EA201590748A1 (ru) Противовирусные соединения против rsv
EA201270373A1 (ru) Ингибиторы jak2 и их применение для лечения миелопролиферативных заболеваний и злокачественной опухоли
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
UA111075C2 (uk) Триазолопіридинові сполуки як інгібітори кінази рім
MX2010009207A (es) Compuestos y composiciones heterociclicos como inhibidores de c-kit y pdgfr cinasa.
EA200971051A1 (ru) Ингибиторы p70 s6 киназы
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
EA201400412A1 (ru) ЗАМЕЩЕННЫЕ БЕНЗИЛИНДАЗОЛЫ ДЛЯ ПРИМЕНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ Bub1 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ГИПЕРПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
EA201170680A1 (ru) Ингибиторы акт и p70 s6-киназы
EA200970156A1 (ru) Пиридизиноновые производные
EA201000113A1 (ru) Пиразольные соединения
EA201390609A1 (ru) ПРОИЗВОДНЫЕ ГИДАНТОИНА, ПОЛЕЗНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Kv3-КАНАЛОВ
EA201170832A1 (ru) Пуриновые соединения
EA201071224A1 (ru) Ингибиторы limk2, композиции, содержащие их, и способы их применения

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU